Drug Trial Radar · NCT06702566
The Effect of Serum Ferritin in irAE
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Jul 4, 2024
Primary completion
Jul 16, 2026
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
Conditions
- Immune-related Adverse Event
- Malignant Solid Tumors
- Acute Leukemia
- Serum Ferritin
Interventions
PD-1 and PD-L1 inhibitorDrug
PD-1 inhibitor includes pembrolizumab,Nivolumab,Sintilimab,tislelizumab,Triplimab,Camrelizumab, Serplulimab. PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.
Targeted drugsDrug
Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
chemotherapy drugsDrug
Chemotherapy drugs are determined based on the investigator's decision.
Primary outcomes
What the sponsor says the trial is designed to measure.
- calculated cut-off value for serum ferritin in the diagnosis of irAETime frame: 1 year
- Determining the sensitivity and specificity of serum ferritin in the diagnosis of irAETime frame: 1 year
- Determining baseline level of serum ferritin predicts irAE occurrenceTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.